- Home
- FENC vs QTRX Comparison
FENC vs QTRX Comparison
Compare FENC & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | QTRX |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.3M | 306.0M |
| IPO Year | 2001 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FENC | QTRX |
|---|---|---|
| Price | $7.57 | $7.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $15.00 | $11.33 |
| AVG Volume (30 Days) | 179.1K | ★ 665.9K |
| Earning Date | 03-09-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $38,790,000.00 | ★ $130,203,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.97 | $28.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.68 | $4.05 |
| 52 Week High | $9.92 | $10.28 |
Technical Indicators
Market Signals| Indicator | FENC | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 56.06 |
| Support Level | $7.35 | $7.07 |
| Resistance Level | $7.82 | $8.77 |
| Average True Range (ATR) | 0.39 | 0.51 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 31.06 | 48.43 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.